Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma

Naito Kurio, Tsuyoshi Shimo, Takuya Fukazawa, Tatsuo Okui, Nur Mohammad Monsur Hassan, Tatsuki Honami, Yuu Horikiri, Shinji Hatakeyama, Munenori Takaoka, Yoshio Naomoto, Akira Sasaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Focal adhesion kinase (FAK) overexpression is frequently found in invasive and metastatic cancers, but its role in oral squamous cell carcinoma is not yet well understood. In order to seek therapies targeting oral squamous cell carcinoma, we developed the novel FAK Tyr397 inhibitor TAE226 and investigated its anti-tumor effects and mechanisms. Materials and Methods: Expression of phosphorylated FAK Tyr397 was examined by immunohistochemical and immunoblot analysis. The effect of TAE226 on in vitro and in vivo studies were confirmed by proliferation, cell cycle, apoptosis and angiogenesis analysis. Results: We found that phosphorylated FAK was highly expressed in human tongue oral squamous cell carcinoma in patients. Importantly, TAE226 greatly suppressed the proliferation, migration and invasion of human oral squamous cell carcinoma SAS cells with an apparent structural change of actin fiber and a loss of cell adhesion. In addition, TAE226 inhibited the expression of phospho-FAK Tyr397 and phospho AKT Ser473, resulting in caspase-mediated apoptosis. Furthermore, oral administration of TAE226 in mice suppressed the growth and angiogenesis of oral squamous cell carcinoma xenografts in vivo. Conclusions: Our results provide compelling evidence that FAK is critically involved in oral squamous cell carcinoma and that the FAK inhibitor TAE226 can potentially be effectively used for the treatment of oral squamous cell carcinoma.

Original languageEnglish
Pages (from-to)1159-1170
Number of pages12
JournalOral Oncology
Volume48
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Focal Adhesion Protein-Tyrosine Kinases
Squamous Cell Carcinoma
Neoplasms
Apoptosis
Caspases
TAE226
Tongue
Heterografts
Cell Adhesion
Oral Administration
Actins
Cell Cycle
Therapeutics
Growth

Keywords

  • Focal adhesion kinase
  • Oral squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma. / Kurio, Naito; Shimo, Tsuyoshi; Fukazawa, Takuya; Okui, Tatsuo; Hassan, Nur Mohammad Monsur; Honami, Tatsuki; Horikiri, Yuu; Hatakeyama, Shinji; Takaoka, Munenori; Naomoto, Yoshio; Sasaki, Akira.

In: Oral Oncology, Vol. 48, No. 11, 11.2012, p. 1159-1170.

Research output: Contribution to journalArticle

Kurio, N, Shimo, T, Fukazawa, T, Okui, T, Hassan, NMM, Honami, T, Horikiri, Y, Hatakeyama, S, Takaoka, M, Naomoto, Y & Sasaki, A 2012, 'Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma', Oral Oncology, vol. 48, no. 11, pp. 1159-1170. https://doi.org/10.1016/j.oraloncology.2012.05.019
Kurio, Naito ; Shimo, Tsuyoshi ; Fukazawa, Takuya ; Okui, Tatsuo ; Hassan, Nur Mohammad Monsur ; Honami, Tatsuki ; Horikiri, Yuu ; Hatakeyama, Shinji ; Takaoka, Munenori ; Naomoto, Yoshio ; Sasaki, Akira. / Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma. In: Oral Oncology. 2012 ; Vol. 48, No. 11. pp. 1159-1170.
@article{1c2d395e99194a05afd06de22b2c6cc4,
title = "Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma",
abstract = "Objectives: Focal adhesion kinase (FAK) overexpression is frequently found in invasive and metastatic cancers, but its role in oral squamous cell carcinoma is not yet well understood. In order to seek therapies targeting oral squamous cell carcinoma, we developed the novel FAK Tyr397 inhibitor TAE226 and investigated its anti-tumor effects and mechanisms. Materials and Methods: Expression of phosphorylated FAK Tyr397 was examined by immunohistochemical and immunoblot analysis. The effect of TAE226 on in vitro and in vivo studies were confirmed by proliferation, cell cycle, apoptosis and angiogenesis analysis. Results: We found that phosphorylated FAK was highly expressed in human tongue oral squamous cell carcinoma in patients. Importantly, TAE226 greatly suppressed the proliferation, migration and invasion of human oral squamous cell carcinoma SAS cells with an apparent structural change of actin fiber and a loss of cell adhesion. In addition, TAE226 inhibited the expression of phospho-FAK Tyr397 and phospho AKT Ser473, resulting in caspase-mediated apoptosis. Furthermore, oral administration of TAE226 in mice suppressed the growth and angiogenesis of oral squamous cell carcinoma xenografts in vivo. Conclusions: Our results provide compelling evidence that FAK is critically involved in oral squamous cell carcinoma and that the FAK inhibitor TAE226 can potentially be effectively used for the treatment of oral squamous cell carcinoma.",
keywords = "Focal adhesion kinase, Oral squamous cell carcinoma",
author = "Naito Kurio and Tsuyoshi Shimo and Takuya Fukazawa and Tatsuo Okui and Hassan, {Nur Mohammad Monsur} and Tatsuki Honami and Yuu Horikiri and Shinji Hatakeyama and Munenori Takaoka and Yoshio Naomoto and Akira Sasaki",
year = "2012",
month = "11",
doi = "10.1016/j.oraloncology.2012.05.019",
language = "English",
volume = "48",
pages = "1159--1170",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma

AU - Kurio, Naito

AU - Shimo, Tsuyoshi

AU - Fukazawa, Takuya

AU - Okui, Tatsuo

AU - Hassan, Nur Mohammad Monsur

AU - Honami, Tatsuki

AU - Horikiri, Yuu

AU - Hatakeyama, Shinji

AU - Takaoka, Munenori

AU - Naomoto, Yoshio

AU - Sasaki, Akira

PY - 2012/11

Y1 - 2012/11

N2 - Objectives: Focal adhesion kinase (FAK) overexpression is frequently found in invasive and metastatic cancers, but its role in oral squamous cell carcinoma is not yet well understood. In order to seek therapies targeting oral squamous cell carcinoma, we developed the novel FAK Tyr397 inhibitor TAE226 and investigated its anti-tumor effects and mechanisms. Materials and Methods: Expression of phosphorylated FAK Tyr397 was examined by immunohistochemical and immunoblot analysis. The effect of TAE226 on in vitro and in vivo studies were confirmed by proliferation, cell cycle, apoptosis and angiogenesis analysis. Results: We found that phosphorylated FAK was highly expressed in human tongue oral squamous cell carcinoma in patients. Importantly, TAE226 greatly suppressed the proliferation, migration and invasion of human oral squamous cell carcinoma SAS cells with an apparent structural change of actin fiber and a loss of cell adhesion. In addition, TAE226 inhibited the expression of phospho-FAK Tyr397 and phospho AKT Ser473, resulting in caspase-mediated apoptosis. Furthermore, oral administration of TAE226 in mice suppressed the growth and angiogenesis of oral squamous cell carcinoma xenografts in vivo. Conclusions: Our results provide compelling evidence that FAK is critically involved in oral squamous cell carcinoma and that the FAK inhibitor TAE226 can potentially be effectively used for the treatment of oral squamous cell carcinoma.

AB - Objectives: Focal adhesion kinase (FAK) overexpression is frequently found in invasive and metastatic cancers, but its role in oral squamous cell carcinoma is not yet well understood. In order to seek therapies targeting oral squamous cell carcinoma, we developed the novel FAK Tyr397 inhibitor TAE226 and investigated its anti-tumor effects and mechanisms. Materials and Methods: Expression of phosphorylated FAK Tyr397 was examined by immunohistochemical and immunoblot analysis. The effect of TAE226 on in vitro and in vivo studies were confirmed by proliferation, cell cycle, apoptosis and angiogenesis analysis. Results: We found that phosphorylated FAK was highly expressed in human tongue oral squamous cell carcinoma in patients. Importantly, TAE226 greatly suppressed the proliferation, migration and invasion of human oral squamous cell carcinoma SAS cells with an apparent structural change of actin fiber and a loss of cell adhesion. In addition, TAE226 inhibited the expression of phospho-FAK Tyr397 and phospho AKT Ser473, resulting in caspase-mediated apoptosis. Furthermore, oral administration of TAE226 in mice suppressed the growth and angiogenesis of oral squamous cell carcinoma xenografts in vivo. Conclusions: Our results provide compelling evidence that FAK is critically involved in oral squamous cell carcinoma and that the FAK inhibitor TAE226 can potentially be effectively used for the treatment of oral squamous cell carcinoma.

KW - Focal adhesion kinase

KW - Oral squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84867866187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867866187&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2012.05.019

DO - 10.1016/j.oraloncology.2012.05.019

M3 - Article

C2 - 22766511

AN - SCOPUS:84867866187

VL - 48

SP - 1159

EP - 1170

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 11

ER -